

Resource Summary Report

Generated by T1D on Aug 1, 2026

Cancer Cell Line Encyclopedia

RRID:SCR_013836

Type: Tool

Proper Citation

Cancer Cell Line Encyclopedia (RRID:SCR_013836)

Resource Information

URL: <https://www.broadinstitute.org/ccle/>

Proper Citation: Cancer Cell Line Encyclopedia (RRID:SCR_013836)

Description: A collaborative project between the Broad Institute and the Novartis Institutes for Biomedical Research and its Genomics Institute of the Novartis Research Foundation, with the goal of conducting a detailed genetic and pharmacologic characterization of a large panel of human cancer models. The CCLE also works to develop integrated computational analyses that link distinct pharmacologic vulnerabilities to genomic patterns and to translate cell line integrative genomics into cancer patient stratification. The CCLE provides public access to genomic data, analysis and visualization for about 1000 cell lines.

Abbreviations: CCLE

Resource Type: portal, data or information resource, database, project portal

Defining Citation: [DOI:10.1038/nature11003](https://doi.org/10.1038/nature11003)

Keywords: cancer, cell line, human, human cancer model, genetic, portal, database, FASEB list

Availability: Public

Resource Name: Cancer Cell Line Encyclopedia

Resource ID: SCR_013836

Alternate IDs: r3d100011819

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260801T042723+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Cell Line Encyclopedia.

No alerts have been found for Cancer Cell Line Encyclopedia.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 82 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Sheth AS, et al. (2025) PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. Cancer research communications, 5(4), 648.

Du H, et al. (2025) Super-enhancer-associated LINC00963 promotes metastasis of gastric cancer through epithelial-mesenchymal transition. PloS one, 20(9), e0332396.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. Cancer research communications, 5(9), 1530.

Jiang S, et al. (2025) Significance of Gelsolin Superfamily Genes in Diagnosis, Prognosis and Immune Microenvironment Regulation for Endometrial Cancer. Cancer medicine, 14(4), e70584.

Castro J, et al. (2025) A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. Cancer research, 85(4), 758.

Wen XM, et al. (2025) Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity. Frontiers in immunology, 16, 1477100.

Wang P, et al. (2025) Nicotinamide N-methyltransferase negatively regulates??metastasis-promoting property of cancer-associated fibroblasts in lung adenocarcinoma. Cancer communications (London, England), 45(2), 110.

Wen XM, et al. (2025) FOXP1 is associated with oncogenesis and clinical outcomes in hematologic malignancies. Frontiers in immunology, 16, 1569641.

Qiu SQ, et al. (2025) GLUT1 as a generic biomarker enables near-infrared fluorescence molecular imaging guided precise intraoperative tumor detection in breast cancer. European journal of nuclear medicine and molecular imaging, 52(6), 2171.

Taylor B, et al. (2024) Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replication. Neuro-oncology advances, 6(1), vdae104.

Schott CR, et al. (2024) Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(4), 849.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. *Cancer research communications*, 4(12), 3084.

Liu W, et al. (2024) Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer. *Scientific reports*, 14(1), 19025.

Sawant NV, et al. (2024) VesiX cetylpyridinium chloride is rapidly bactericidal and reduces uropathogenic *Escherichia coli* bladder epithelial cell invasion in vitro. *Microbiology spectrum*, 12(3), e0271223.

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, OF1.

Hayes TK, et al. (2024) Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. *Nature communications*, 15(1), 2742.

Liang B, et al. (2024) Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer. *Cancer letters*, 587, 216702.

Dovrolis N, et al. (2024) Pan-Cancer Insights: A Study of Microbial Metabolite Receptors in Malignancy Dynamics. *Cancers*, 16(24).

Turan T, et al. (2023) iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-cell RNA-Seq Data and Differentiate Cell Type-Specific Markers of Immune-Cell Infiltration. *Cancer immunology research*, 11(6), 732.

Zhang B, et al. (2023) An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer. *Advances in therapy*, 40(10), 4339.